A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671
Status:
Completed
Trial end date:
2020-02-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and
pharmacodynamics of multiple ascending doses of ABP-671 administered orally in subjects with
hyperuricemia.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.